Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9754238 | 0.79 | — | — | |
| SCHEMBL6897137 | 0.76 | ITGB3 (0.34) | — | |
| SCHEMBL12778338 | 0.73 | MIF (0.31) | — | |
| SCHEMBL12778341 | 0.73 | MIF (0.31) | — | |
| SCHEMBL6894909 | 0.70 | — | — | |
| SCHEMBL14183657 | 0.66 | — | — | |
| SCHEMBL6897181 | 0.65 | TSHR (0.34) | — | |
| SCHEMBL15367982 | 0.64 | RAB9A (0.32) | — | |
| SCHEMBL15367987 | 0.64 | RAB9A (0.32) | — | |
| SCHEMBL7996426 | 0.62 | RAB9A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786310-B2 | Acetic acid (2-benzyl-3-(2-hydroxy-ethyl)-3-isobutyl-isoxazolidin-5- ylmethylene)-hydrazide; fused to a DNA binding domain to repress or activate gene expression; libraries; gene therapy | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786310-B2 | Acetic acid (2-benzyl-3-(2-hydroxy-ethyl)-3-isobutyl-isoxazolidin-5- ylmethylene)-hydrazide; fused to a DNA binding domain to repress or activate gene expression; libraries; gene therapy | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786310-B2 | Acetic acid (2-benzyl-3-(2-hydroxy-ethyl)-3-isobutyl-isoxazolidin-5- ylmethylene)-hydrazide; fused to a DNA binding domain to repress or activate gene expression; libraries; gene therapy | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-08-31 | — | — | US | disclosed |
| US-20070105151-A1 | Small molecule transcriptional activation domains | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105151-A1 | Small molecule transcriptional activation domains | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105151-A1 | Small molecule transcriptional activation domains | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105151-A1 | Small molecule transcriptional activation domains | SUB1, ATF1, ILF3 | SORT1 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.